SNT Stock Overview
Syntara Limited operates as a clinical stage drug development company that focuses on blood-related cancers.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Syntara Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.017 |
52 Week High | AU$0.063 |
52 Week Low | AU$0.014 |
Beta | 0.54 |
1 Month Change | -15.00% |
3 Month Change | 0% |
1 Year Change | -72.13% |
3 Year Change | -79.76% |
5 Year Change | -93.46% |
Change since IPO | -96.22% |
Recent News & Updates
Recent updates
Syntara Limited's (ASX:SNT) Low P/S No Reason For Excitement
Mar 14We're Hopeful That Pharmaxis (ASX:PXS) Will Use Its Cash Wisely
Feb 28Shareholders May Not Be So Generous With Pharmaxis Ltd's (ASX:PXS) CEO Compensation And Here's Why
Oct 27Key Things To Understand About Pharmaxis' (ASX:PXS) CEO Pay Cheque
Mar 01We Think Pharmaxis (ASX:PXS) Can Afford To Drive Business Growth
Jan 04Shareholder Returns
SNT | AU Pharmaceuticals | AU Market | |
---|---|---|---|
7D | 13.3% | -3.3% | 0.4% |
1Y | -72.1% | 29.3% | 6.0% |
Return vs Industry: SNT underperformed the Australian Pharmaceuticals industry which returned 29.3% over the past year.
Return vs Market: SNT underperformed the Australian Market which returned 6% over the past year.
Price Volatility
SNT volatility | |
---|---|
SNT Average Weekly Movement | 12.3% |
Pharmaceuticals Industry Average Movement | 10.8% |
Market Average Movement | 8.9% |
10% most volatile stocks in AU Market | 17.6% |
10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: SNT's share price has been volatile over the past 3 months.
Volatility Over Time: SNT's weekly volatility (12%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 27 | Gary Phillips | www.syntaratx.com.au |
Syntara Limited operates as a clinical stage drug development company that focuses on blood-related cancers. Its lead product candidate is PXS-5505, which is in phase 2 trial for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue leading to loss of red and white blood cells and platelets. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023.
Syntara Limited Fundamentals Summary
SNT fundamental statistics | |
---|---|
Market cap | AU$20.30m |
Earnings (TTM) | -AU$10.69m |
Revenue (TTM) | AU$19.18m |
1.1x
P/S Ratio-1.9x
P/E RatioIs SNT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SNT income statement (TTM) | |
---|---|
Revenue | AU$19.18m |
Cost of Revenue | AU$11.31m |
Gross Profit | AU$7.87m |
Other Expenses | AU$18.56m |
Earnings | -AU$10.69m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
Earnings per share (EPS) | -0.009 |
Gross Margin | 41.03% |
Net Profit Margin | -55.77% |
Debt/Equity Ratio | 0% |
How did SNT perform over the long term?
See historical performance and comparison